Olufunmilayo Olopade to Immunohistochemistry
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Immunohistochemistry.
Connection Strength
0.309
-
Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
Score: 0.086
-
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
Score: 0.038
-
Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res. 2001 Jun; 7(6):1676-82.
Score: 0.037
-
Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am. 1997 Jul-Aug; 3(4):230-7.
Score: 0.028
-
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013 Dec; 34(6):3945-58.
Score: 0.021
-
Clinical implications of ERß methylation on sporadic breast cancers in Chinese women. Med Oncol. 2012 Sep; 29(3):1569-75.
Score: 0.019
-
Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol. 2012 Sep; 29(3):1543-53.
Score: 0.019
-
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009 Mar 16; 7:9.
Score: 0.016
-
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9.
Score: 0.014
-
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006 Feb; 19(2):264-71.
Score: 0.013
-
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope. 2002 Mar; 112(3):472-81.
Score: 0.010
-
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
Score: 0.009